Updates in the Epidemiology of Fatty Liver and its Consequences in Saudi Arabia: A Review

Badriah Mohammed Alanazi *

KFMC, Riyadh, Saudi Arabia.

*Author to whom correspondence should be addressed.


Abstract

The occurrence of non-alcoholic fatty liver disease has exponentially increased worldwide. A considerable majority of cases advance to non-Alcoholic Steatohepatitis in the nonexistence of therapeutic measures, which increases morbidity and death. Because the initial phases of the illness are frequently clinically unapparent, the identification of non-alcoholic fatty liver disease frequently rests on biochemical and radiographic studies. Concentrated life modifications that result in weight loss are the mainstay of the disease's management. Therapeutic treatments that could be additional to lifestyle changes once essential for case managing comprise insulin sensitizers, antioxidants, incretin-based pharmaceuticals, cholesterol depressing mediators, weight reduction therapies, bariatric surgery, and liver transplantation. For non-alcoholic fatty liver disease to be managed more effectively and lessen its worldwide impact, research must be conducted continuously.

Keywords: Fatty liver, NAFLD, NASH, epidemiology


How to Cite

Alanazi, B. M. (2022) “Updates in the Epidemiology of Fatty Liver and its Consequences in Saudi Arabia: A Review”, Journal of Pharmaceutical Research International, 34(46B), pp. 39–46. doi: 10.9734/jpri/2022/v34i46B36387.